MindWalk Holdings (HYFT) Cash & Equivalents (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Cash & Equivalents of $8.4 million for Q2 2026, up 10.29% year-over-year from $7.6 million in Q2 2025, and down 17.45% quarter-over-quarter from $10.1 million in Q1 2026.
MindWalk Holdings (HYFT) Cash & Equivalents (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Cash & Equivalents for 7 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash & Equivalents rose 10.29% year-over-year to $8.4 million; the TTM figure through Apr 2026 stood at $8.4 million (up 10.29% YoY), while the FY2026 annual figure was $8.4 million, up 7.96% from the prior year.
- Cash & Equivalents slipped to $8.4 million in Q2 2026 per HYFT's latest filing, from $10.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $26.1 million in Q1 2022 and bottomed at $2.6 million in Q2 2024.
- Historically, Cash & Equivalents has averaged $9.1 million across 5 years, with a median of $8.0 million in 2026.
- Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 73.94% — and 2025, when it jumped 348.79%.
- MindWalk Holdings' Cash & Equivalents stood at $11.3 million in 2022, then tumbled by 60.3% to $4.5 million in 2023, then plunged by 41.1% to $2.7 million in 2024, then soared by 348.79% to $11.9 million in 2025, then retreated by 29.66% to $8.4 million in 2026.
- Business Quant data shows HYFT's Cash & Equivalents at $8.4 million in Q2 2026, $10.1 million in Q1 2026, and $11.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 8.37 Mn |
| Jan 31, 2026 | 10.14 Mn |
| Oct 31, 2025 | 11.90 Mn |
| Jul 31, 2025 | 3.56 Mn |
| Apr 30, 2025 | 7.59 Mn |
| Jan 31, 2025 | 9.16 Mn |
| Oct 31, 2024 | 2.65 Mn |
| Jul 31, 2024 | 2.92 Mn |
| Apr 30, 2024 | 2.61 Mn |
| Jan 31, 2024 | 4.65 Mn |
| Oct 31, 2023 | 4.50 Mn |
| Jul 31, 2023 | 5.10 Mn |
| Apr 30, 2023 | 6.18 Mn |
| Jan 31, 2023 | 8.46 Mn |
| Oct 31, 2022 | 11.34 Mn |
| Jul 31, 2022 | 14.96 Mn |
| Apr 30, 2022 | 23.72 Mn |
| Jan 31, 2022 | 26.06 Mn |
| Oct 31, 2021 | 30.51 Mn |
| Jul 31, 2021 | 33.13 Mn |